JOUNCE THERAPEUTICS INC (JNCE) Stock News

NASDAQ:JNCE - Nasdaq - US4811161011 - Common Stock - Currency: USD

1.88 -0.05 (-2.59%)

After market: 1.92 +0.04 (+2.13%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

JNCE Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Jounce Therapeutics, Inc.

Jounce Therapeutics Announces Closing of Tender Offer

2 years ago - By: Jounce Therapeutics, Inc.

Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

2 years ago - By: Benzinga - Mentions: CRBP BLPH PRVB RPHM

Top 5 Health Care Stocks That May Crash In March

2 years ago - By: Benzinga

Jounce Therapeutics Says JTX-8064/Pimivalimab Shows Deep, Durable Responses In Pretreated Ovarian Cancer Patients

2 years ago - By: InvestorPlace - Mentions: BOXD INPX LYLT

Why Is Boxed (BOXD) Stock Down 41% Today?

2 years ago - By: InvestorPlace - Mentions: AMC

Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?

2 years ago - By: Halper Sadeh LLC

JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders

2 years ago - By: Seeking Alpha

Jounce stock jumps as Concentra agrees to buy (NASDAQ:JNCE)

2 years ago - By: Jounce Therapeutics, Inc.

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

2 years ago - By: Jounce Therapeutics, Inc.

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

2 years ago - By: InvestorPlace - Mentions: INPX LYLT

Why Is Inpixon (INPX) Stock Down 34% Today?

2 years ago - By: InvestorPlace - Mentions: STBX SWVL LYLT HUBC ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

2 years ago - By: Jounce Therapeutics, Inc.

Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

2 years ago - By: Kahn Swick & Foti, LLC

JOUNCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Jounce Therapeutics, Inc. - JNCE

2 years ago - By: Seeking Alpha - Mentions: RJF

Jounce Therapeutics downgraded to market perform at Raymond James (NASDAQ:JNCE)

2 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Jounce Therapeutics, Inc. has obtained a Fair Price in its transaction with RedX Pharma